Recurrence Score(®) Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial

SIMPLE SUMMARY: Hormone receptor-positive (HR+), HER2-negative (HER2−) is the most common breast cancer subtype (approximately 75% of all breast cancer cases). Adjuvant chemotherapy can be administered to patients that undergo operative tumor removal with only few metastatic axillary lymph nodes (0–...

Descripción completa

Detalles Bibliográficos
Autores principales: Dannehl, Dominik, Engler, Tobias, Volmer, Lea L., Staebler, Annette, Fischer, Anna K., Weiss, Martin, Hahn, Markus, Walter, Christina B., Grischke, Eva-Maria, Fend, Falko, Taran, Florin-Andrei, Brucker, Sara Y., Hartkopf, Andreas D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657368/
https://www.ncbi.nlm.nih.gov/pubmed/36358784
http://dx.doi.org/10.3390/cancers14215365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657368/
https://www.ncbi.nlm.nih.gov/pubmed/36358784
http://dx.doi.org/10.3390/cancers14215365

Ejemplares similares